Management of Clostridioides difficile Infection.

Area of Science:

• Infectious Diseases
• Healthcare Epidemiology
• Critical Care Medicine

Background:

• Clostridioides difficile infection (CDI) is a leading cause of hospital-acquired infections in the US.
• Critically ill patients face a high incidence and severity of CDI, with treatment challenges due to comorbidities and ongoing antibiotic use.
• High recurrence rates and mortality underscore the urgent need for improved CDI management strategies.

Purpose of the Study:

• To review the 2017 updated clinical practice guidelines for Clostridioides difficile infection.
• To incorporate new information on existing drugs and novel therapeutics for CDI treatment.
• To highlight the role of critical care nurses in mitigating CDI risk.

Main Methods:

• Review of the 2017 Society for Health-care Epidemiology of America and Infectious Diseases Society of America guidelines.
• Analysis of clinical pharmacology of established and emerging CDI drugs.
• Examination of nursing interventions for CDI prevention in critical care settings.

Main Results:

• Updated recommendations for CDI treatment, including pharmacotherapy.
• Insights into the clinical pharmacology of both old and new CDI drugs.
• Emphasis on the critical role of nurses in reducing CDI transmission and patient risk.

Conclusions:

• The 2017 guidelines provide updated strategies for managing Clostridioides difficile infection.
• New pharmacological agents and a better understanding of existing ones offer improved treatment options.
• Proactive nursing interventions are crucial for minimizing CDI risk in hospitalized patients.